UPDATE: Canaccord Genuity Reiterates Buy Rating, Lowers PT on Anacor Pharmaceuticals

In a report published Wednesday, Canaccord Genuity reiterated its Buy rating on Anacor Pharmaceuticals (NASDAQ: ANAC ), but lowered its price target from $9.00 to $5.00. Canaccord Genuity noted, “Maintaining BUY but lowering target to $5 from $9 as tavaborole's potential in onychomycosis becomes uncertain and AN2728 potential in AD